Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Carla J. Greenbaum, Dana VanBuecken, Sandra Lord
Drugs (2019) Vol. 79, Iss. 1, pp. 43-61
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
Manuela Battaglia, Simi Ahmed, Mark S. Anderson, et al.
Diabetes Care (2019) Vol. 43, Iss. 1, pp. 5-12
Open Access | Times Cited: 278
Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes
Marco Infante, Camillo Ricordi, Janine Sanchez, et al.
Nutrients (2019) Vol. 11, Iss. 9, pp. 2185-2185
Open Access | Times Cited: 242
Progress in the Relationship between Vitamin D Deficiency and the Incidence of Type 1 Diabetes Mellitus in Children
Lianping He, Yu-Xin Song, Ting Zhu, et al.
Journal of Diabetes Research (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 101
Heterogeneity and endotypes in type 1 diabetes mellitus
María J. Redondo, Noel G. Morgan
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 9, pp. 542-554
Closed Access | Times Cited: 64
Preventing type 1 diabetes in childhood
Colin Dayan, Rachel Besser, Richard A. Oram, et al.
Science (2021) Vol. 373, Iss. 6554, pp. 506-510
Open Access | Times Cited: 78
Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial
Danijela Tatović, Ashish Marwaha, Peter Taylor, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2657-2666
Open Access | Times Cited: 10
Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes
Mohammad Amin Honardoost, Andreas Adinatha, Florian Schmidt, et al.
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 6
Birth and coming of age of islet autoantibodies
Ezio Bonifacio, Peter Achenbach
Clinical & Experimental Immunology (2019) Vol. 198, Iss. 3, pp. 294-305
Open Access | Times Cited: 45
Protective Role of St. John’s Wort and Its Components Hyperforin and Hypericin against Diabetes through Inhibition of Inflammatory Signaling: Evidence from In Vitro and In Vivo Studies
Michela Novelli, Pellegrino Masiello, Pascale Beffy, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8108-8108
Open Access | Times Cited: 41
INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes
David B. Dunger, Sylvaine F. A. Bruggraber, Adrian Mander, et al.
Trials (2022) Vol. 23, Iss. 1
Open Access | Times Cited: 25
Inhibition of polyamine biosynthesis preserves β cell function in type 1 diabetes
Emily K. Sims, Abhishek Kulkarni, Audrey Hull, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101261-101261
Open Access | Times Cited: 15
Classification of type 1 diabetes: A pathogenic and treatment-based classification
Shivani Patel, Spiros Fourlanos, Jerry R. Greenfield
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2024) Vol. 18, Iss. 3, pp. 102986-102986
Closed Access | Times Cited: 4
T helper 17 cells and interleukin-17 immunity in type 1 diabetes: From pathophysiology to targeted immunotherapies
Georgi Vasilev, Maria Kokudeva, Elina Siliogka, et al.
World Journal of Diabetes (2025) Vol. 16, Iss. 4
Closed Access
New therapeutic approaches for type 1 diabetes: Disease-modifying therapies
Géza Nagy, Tekla Evelin Szekely, Anikó Somogyi, et al.
World Journal of Diabetes (2022) Vol. 13, Iss. 10, pp. 835-850
Open Access | Times Cited: 16
Continuous glucose monitoring has an increasing role in pre-symptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing
Kriti Joshi, Mark Harris, Andrew Cotterill, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2023) Vol. 62, Iss. 1, pp. 41-49
Open Access | Times Cited: 9
Type 1 Diabetes and Other Autoimmune Disorders in Children
E Grasso, Francesco Chiarelli
Pediatric Diabetes (2024) Vol. 2024, pp. 1-14
Open Access | Times Cited: 3
Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial
Thomas F. Dejgaard, Christian S. Frandsen, Urd Kielgast, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 4905-4915
Closed Access | Times Cited: 3
Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D
Peter S. Linsley, S. Alice Long
Current Opinion in Endocrinology Diabetes and Obesity (2019) Vol. 26, Iss. 4, pp. 213-218
Open Access | Times Cited: 27
Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID‐19 pandemic
Marco Infante, Camillo Ricordi, Andrea Fabbri
Journal of Diabetes (2020) Vol. 12, Iss. 9, pp. 659-667
Open Access | Times Cited: 26
Autoimmune thyroid disease and type 1 diabetes mellitus: same pathogenesis; new perspective?
Liyan Li, Shudong Liu, Junxia Yu
Therapeutic Advances in Endocrinology and Metabolism (2020) Vol. 11
Open Access | Times Cited: 24
Autoantibody-Negative Type 1 Diabetes: A Neglected Subtype
Shivani Patel, S. Cindy, Spiros Fourlanos, et al.
Trends in Endocrinology and Metabolism (2021) Vol. 32, Iss. 5, pp. 295-305
Closed Access | Times Cited: 23
Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Susana Nogueira Diniz, et al.
International Immunopharmacology (2021) Vol. 95, pp. 107518-107518
Closed Access | Times Cited: 21
Diabetes type 1: Can it be treated as an autoimmune disorder?
Natalia G. Vallianou, Theodora Stratigou, Eleni Geladari, et al.
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 22, Iss. 4, pp. 859-876
Closed Access | Times Cited: 19
Autoimmune (Type 1) diabetes
Francesca D’Addio, Moufida Ben Nasr, Maria Elena Lunati, et al.
Elsevier eBooks (2024), pp. 585-601
Closed Access | Times Cited: 2
Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all
Theocharis Koufakis, Niki Katsiki, Pantelis Zebekakis, et al.
Journal of Diabetes (2019) Vol. 12, Iss. 2, pp. 110-118
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top